[Retracted] Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma

Table 3

Comparison of overall survival rates between the observation group and the control group.

Group	Number of cases	6 months	12 months	24 months
Observation group	31	29 (93.5%)	25 (80.6%)	20 (64.5%)
Control group	31	29 (93.5%)	21 (67.7%)	12 (38.7%)
value		0.694	0.384	0.037